BlackRock reports 5.01% stake in IRADIMED

BlackRock, Inc. reported a passive ownership stake in IRADIMED CORP common stock on a Schedule 13G. As of June 30, 2026, BlackRock beneficially owned 641,128 shares, representing 5.01% of the outstanding common stock.

Rhea-AI Filing Summary

BlackRock, Inc. reported a passive ownership stake in IRADIMED CORP common stock on a Schedule 13G. As of June 30, 2026, BlackRock beneficially owned 641,128 shares, representing 5.01% of the outstanding common stock.

BlackRock reported sole voting power over 622,925 shares and sole dispositive power over 641,128 shares, with no shared voting or dispositive power. The filing notes that various underlying clients have rights to dividends or sale proceeds, but no single client holds more than five percent of IRADIMED’s outstanding common shares.

Key Figures

Beneficial ownership: 641,128 shares Percent of class: 5.01 % Sole voting power: 622,925 shares +3 more

6 metrics

Beneficial ownership 641,128 shares Common stock beneficially owned by BlackRock as of June 30, 2026

Percent of class 5.01 % Percentage of IRADIMED CORP common stock class held by BlackRock

Sole voting power 622,925 shares Shares over which BlackRock has sole power to vote or direct the vote

Shared voting power 0 Shares over which BlackRock has shared power to vote or direct the vote

Sole dispositive power 641,128 shares Shares over which BlackRock has sole power to dispose or direct disposition

Shared dispositive power 0 Shares over which BlackRock has shared power to dispose or direct disposition

Key Terms

Schedule 13G, beneficially owned, Sole Voting Power, dispositive power, +1 more

5 terms

Schedule 13G regulatory

"BlackRock filed this Schedule 13G regarding IRADIMED CORP"

A Schedule 13G is a formal document that investors file with the government when they acquire a large ownership stake in a company, usually for investment purposes rather than control. It helps keep the public informed about who owns significant parts of a company's shares, which can influence how the company is managed and how investors make decisions. Filing this schedule is important for transparency and understanding the ownership landscape of publicly traded companies.

beneficially owned financial

"reflects the securities beneficially owned, or deemed to be beneficially owned"

Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.

Sole Voting Power financial

"5 | Sole Voting Power 622,925.00 6 | Shared Voting Power 0.00"

Sole voting power is the exclusive right to cast votes attached to a shareholder’s stock without needing approval from anyone else. Like holding the only remote control for a TV, it lets that holder decide corporate matters such as board members, mergers, and policy changes, making it important to investors because it concentrates control and can strongly influence a company’s strategy and the value of its shares.

dispositive power financial

"Sole Dispositive Power 641,128.00 8 | Shared Dispositive Power 0.00"

Dispositive power is the authority to decide the final outcome of an asset, legal claim, contract, or corporate action — in effect the power to dispose of or resolve something. For investors it matters because whoever holds that authority can determine who gets paid, who controls an asset or vote, and how risks and returns are allocated; think of it like holding the key that lets you lock in the winner or loser in a deal.

parent holding company regulatory

"Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What ownership stake in IRMD does BlackRock report on this Schedule 13G?

BlackRock reports beneficial ownership of 641,128 shares of IRADIMED CORP common stock, representing 5.01% of the class as of June 30, 2026. This reflects holdings of certain BlackRock business units only.

How much voting power over IRMD shares does BlackRock have?

BlackRock reports sole voting power over 622,925 shares of IRADIMED CORP common stock and no shared voting power. This indicates only BlackRock-controlled voting for those shares, subject to its underlying client arrangements.

Does any single BlackRock client hold over 5% of IRMD shares?

No. The filing states that various persons have rights to dividends or sale proceeds, but no one person’s interest exceeds five percent of IRADIMED CORP’s total outstanding common shares through these BlackRock-managed holdings.

Is BlackRock’s IRMD position held with sole or shared dispositive power?

BlackRock reports sole dispositive power over 641,128 shares of IRADIMED CORP and no shared dispositive power. Sole dispositive power typically means BlackRock can direct how and when those shares are sold or otherwise disposed.

What type of filing did BlackRock make for its IRMD holdings?

BlackRock filed a Schedule 13G regarding IRADIMED CORP. Schedule 13G is used for reporting passive beneficial ownership of more than 5% of a class of a company’s registered equity securities.

Who signed the Schedule 13G related to IRMD on behalf of BlackRock?

The Schedule 13G was signed by Spencer Fleming, identified as a Managing Director at BlackRock. The signature is supported by a Power of Attorney attached as Exhibit 24 to the filing.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 07/28/2026 - 04:46 PM Accepted by SEC EDGAR 07/28/2026 - 04:44 PM Learn about SEC filing dates

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

IRADIMED CORP

(Name of Issuer)

Common Stock

(Title of Class of Securities)

46266A109

(CUSIP Number)

06/30/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

schemaVersion:

SCHEDULE 13G

CUSIP Number(s): 46266A109

1

Names of Reporting Persons

BlackRock, Inc.

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 622,925.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 641,128.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

641,128.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

5.01 %

12

Type of Reporting Person (See Instructions)

HC

SCHEDULE 13G

Item 1.
(a)	Name of issuer: IRADIMED CORP
(b)	Address of issuer's principal executive offices: 12705 Ingenuity Drive Orlando FL 32826
Item 2.
(a)	Name of person filing: BlackRock, Inc. In accordance with SEC Release No. 34-39538 (January 12, 1998), this Schedule 13G reflects the securities beneficially owned, or deemed to be beneficially owned, by certain business units (collectively, the "Reporting Business Units") of BlackRock, Inc. and its subsidiaries and affiliates. It does not include securities, if any, beneficially owned by other business units whose beneficial ownership of securities are disaggregated from that of the Reporting Business Units in accordance with such release.
(b)	Address or principal business office or, if none, residence: BlackRock, Inc., 50 Hudson Yards New York, NY 10001
(c)	Citizenship: See Item 4 of Cover Page
(d)	Title of class of securities: Common Stock
(e)	CUSIP Number(s): 46266A109
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: 641128
(b)	Percent of class: 5.01 %
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 622925
	(ii) Shared power to vote or to direct the vote: 0
	(iii) Sole power to dispose or to direct the disposition of: 641128
	(iv) Shared power to dispose or to direct the disposition of: 0
Item 5.	Ownership of 5 Percent or Less of a Class.
	Not Applicable
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required. Various persons have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of the common stock of IRADIMED CORP. No one person's interest in the common stock of IRADIMED CORP is more than five percent of the total outstanding common shares.
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary. See Exhibit 99
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

BlackRock, Inc.

Signature:	Spencer Fleming
Name/Title:	Managing Director
Date:	07/28/2026

Exhibit Information

Exhibit 24: Power of Attorney Exhibit 99: Item 7